Family History of Prostate Cancer in Men Being Followed by Active Surveillance Does Not Increase Risk of Being Diagnosed With High-grade Disease EDITORIAL COMMENT

被引:0
|
作者
Thomas, Christian [1 ]
Thueroff, Joachim W. [1 ]
机构
[1] Johannes Gutenberg Univ Mainz, Dept Urol, Mainz, Germany
关键词
D O I
10.1016/j.urology.2014.10.061
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To assess whether men with a family history of prostate cancer are more likely to fail active surveillance because of recategorization of their tumors on subsequent surveillance biopsies. METHODS Men enrolled in an institutional review board-approved active surveillance program were studied, and data on first-and/or second-degree family history of prostate cancer was collected. Analyses were performed to compare the frequency of family history with recategorization (higher grade or volume disease) on surveillance biopsies. RESULTS Men with and without family history were recategorized with higher grade disease at a similar frequency (30.9% vs 32.8%). There was no evidence that men with a family history with higher grade disease had more aggressive pathology at the time of radical prostatectomy than men without a family history. Although those with a family history tended to have a shorter time period to recategorization with more positive cores, the difference was not significant. CONCLUSION Our results suggest that men with a family history of prostate cancer are not at an increased risk for recategorization on active surveillance. Men with a family history of prostate cancer should not be deterred from considering active surveillance as a treatment option. (C) 2015 Elsevier Inc.
引用
收藏
页码:746 / 746
页数:1
相关论文
共 48 条
  • [21] Identifying Candidates for Active Surveillance: An Evaluation of the Repeat Biopsy Strategy for Men with Favorable Risk Prostate Cancer EDITORIAL COMMENT
    Haas, Gabriel P.
    Delongchamps, Nicolas Barry
    JOURNAL OF UROLOGY, 2012, 188 (03): : 767 - 768
  • [22] RISK OF ADVERSE PATHOLOGY AFTER DEFERRED PROSTATECTOMY FOR GRADE GROUP 1 AND 2 PROSTATE CANCER BEING MANAGED BY ACTIVE SURVEILLANCE
    Williams, Cheyenne
    Daneshvar, Michael
    Gomella, Patrick
    O'Connor, Luke
    Gurram, Sandeep
    Choyke, Peter
    Wood, Bradford
    Turkbey, Baris
    Merino, Maria
    Pinto, Peter
    JOURNAL OF UROLOGY, 2022, 207 (05): : E744 - E744
  • [23] Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance EDITORIAL COMMENT
    Morash, Chris
    JOURNAL OF UROLOGY, 2017, 198 (03): : 598 - 599
  • [24] Low risk prostate cancer patients with negative confirmatory biopsies during active surveillance are at low risk of being treated for their disease
    Tabcheh, A.
    Abi, Chebel J.
    Ingels, A.
    Champy, C.
    Vordos, D.
    Boustany, J.
    Gerbaud, F.
    Miro, Padovani M.
    De La Taille, A.
    EUROPEAN UROLOGY, 2021, 79 : S1457 - S1458
  • [25] Identifying Men Who Can Remain on Active Surveillance Despite Biopsy Reclassification to Grade Group 2 Prostate Cancer EDITORIAL COMMENT
    Prasad, Sandip M.
    Kovac, Evan
    JOURNAL OF UROLOGY, 2023, 210 (01): : 107 - 107
  • [26] Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study
    Lin, Daniel W.
    Newcomb, Lisa F.
    Brown, Marshall D.
    Sjoberg, Daniel D.
    Dong, Yan
    Brooks, James D.
    Carroll, Peter R.
    Cooperberg, Matthew
    Dash, Atreya
    Ellis, William J.
    Fabrizio, Michael
    Gleave, Martin E.
    Morgan, Todd M.
    Nelson, Peter S.
    Thompson, Ian M.
    Wagner, Andrew A.
    Zheng, Yingye
    EUROPEAN UROLOGY, 2017, 72 (03) : 448 - 454
  • [27] Re: Contemporary Use of Initial Active Surveillance among Men in Michigan with Low-Risk Prostate Cancer Editorial Comment
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2015, 193 (01): : 128 - 129
  • [28] The association of male pattern baldness and risk of cancer and high-grade disease among men presenting for prostate biopsy
    Al Edwan, Ghazi
    Bhindi, Bimal
    Margel, David
    Chadwick, Karen
    Finelli, Antonio
    Zlotta, Alexandre
    Trachtenberg, John
    Fleshner, Neil
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2016, 10 (11-12): : E424 - E427
  • [29] Lipid Profile, PCSK9, ANGPTL3 and Lipoprotein (a) Levels in Men Diagnosed With Localized High-Grade Prostate Cancer and Men At-Risk of Prostate Cancer
    Bergeron, Ann-Charlotte
    Wong-Chong, Emilie
    Joncas, France-Helene
    Castonguay, Chloe
    Calon, Frederic
    Seidah, Nabil G.
    Blais, Jonatan
    Robitaille, Karine
    Bergeron, Alain
    Fradet, Vincent
    Gangloff, Anne
    CANCER MEDICINE, 2025, 14 (03):
  • [30] Predicting the risk of harboring high-grade disease for patients diagnosed with prostate cancer scored as Gleason ≤ 6 on biopsy cores
    Thomas Seisen
    Françoise Roudot-Thoraval
    Pierre Olivier Bosset
    Aurélien Beaugerie
    Yves Allory
    Dimitri Vordos
    Claude-Clément Abbou
    Alexandre De La Taille
    Laurent Salomon
    World Journal of Urology, 2015, 33 : 787 - 792